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Abstract 
Background: Type 2 diabetes (T2D) causes substantial disease burden and is projected to affect an increasing num-
ber of people in coming decades. This study provides projected estimates of life years free of type 2 diabetes (T2D) 
and years of life lost ( YLL ) associated with T2D for Germany in the years 2015 and 2040.
Methods: Based on an illness-death model and the associated mathematical relation between prevalence, incidence 
and mortality, we projected the prevalence of diagnosed T2D using currently available data on the incidence rate of 
diagnosed T2D and mortality rates of people with and without diagnosed T2D. Projection of prevalence was achieved 
by integration of a partial differential equation, which governs the illness-death model. These projected parameters 
were used as input values to calculate life years free of T2D and YLL associated with T2D for the German population 
aged 40 to 100 years in the years 2015 and 2040, while accounting for different assumptions on future trends in T2D 
incidence and mortality.
Results: Assuming a constant incidence rate, women and men at age 40 years in 2015 will live approximately 
38 years and 33 years free of T2D, respectively. Up to the year 2040, these numbers are projected to increase by 
1.0 years and 1.3 years. Assuming a decrease in T2D-associated excess mortality of 2% per year, women and men aged 
40 years with T2D in 2015 will be expected to lose 1.6 and 2.7 years of life, respectively, compared to a same aged 
person without T2D. In 2040, these numbers would reduce by approximately 0.9 years and 1.6 years. This translates to 
10.8 million and 6.4 million YLL in the German population aged 40–100 years with prevalent T2D in 2015 and 2040, 
respectively.
Conclusions: Given expected trends in mortality and no increase in T2D incidence, the burden due to premature 
mortality associated with T2D will decrease on the individual as well as on the population level. In addition, the 
expected lifetime without T2D is likely to increase. However, these trends strongly depend on future improvements of 
excess mortality associated with T2D and future incidence of T2D, which should motivate increased efforts of primary 
and tertiary prevention.
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Background
The prevalence of diabetes has increased globally and 
considering all types of diabetes, it is estimated that there 
were 415 million cases in 2015 in the population aged 
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20–79 years [1]. Due to increased mortality and morbid-
ity, diabetes is one of the leading causes of disease burden 
in many countries [2]. Commonly, disease burden due to 
increased mortality is quantified by years of life lost due 
to premature death ( YLL ). YLLs inform about the average 
life time a person loses through premature death from a 
certain disease.
T2D as an underlying cause of death still imposes a 
large disease burden in Germany, however trends indi-
cate that the burden is shifting towards increased mor-
bidity [3]. This is partly caused by reductions in the 
mortality rate among people with T2D in the last decades 
[4–6]. Hence, the average life time spent with T2D for the 
individual and in the population is likely to increase [6, 7]. 
Thus, besides YLL , quantifying lifetime free of T2D (T2D 
free life expectancy), is one way to give a more complete 
picture of the burden T2D imposes on a population.
Whilst there are several approaches to estimate YLL [8, 
9], the global burden of disease study (GBD) probably is 
the most widely known application of the concept [2]. In 
GBD, YLL are based on the number and causes of deaths 
in a given year and the expected remaining life expec-
tancy at the age of death. For instance, it was estimated 
that in Germany, 256,217  years of life were lost due to 
diabetes as cause of death in 2017, ranking diabetes at 
the 13th position in the causes of YLL [10]. The GBD 
estimates are based on a global standard life expectancy. 
Although using a standard life expectancy is well suited 
for between country comparisons, estimates based on 
country-specific life expectancy might be more appro-
priate to inform national policies. For T2D in particu-
lar, there are two methodological specificities with the 
YLL method used in GBD. First, causes of death statis-
tics probably underestimate the number of deaths due to 
T2D [11] as comorbidities and complications of diabetes 
(e.g. cardiovascular diseases), which are highly prevalent 
in people with diabetes and common causes of death, 
are not taken into account by this approach. Second, 
YLL based on observed number of deaths does not con-
sider lower life expectancy of people with T2D. In con-
trast, methods based on excess mortality rates associated 
with T2D (as in [9]) are another approach, which com-
pare people with T2D to people without T2D (includ-
ing comorbidities) with regard to life expectancy. This 
approach might be preferable when the aim is to describe 
the mortality burden associated with prevalent T2D, as 
opposed to the mortality burden among people dying in a 
given year with type 2 diabetes as the documented cause 
of death.
Previous studies estimating YLL associated with preva-
lent T2D relied on cross-sectional mortality rates, for 
instance from period life tables [e.g. 12, 13]. However, life 
expectancy of people alive today depends on mortality 
rates these people will experience in the future. There-
fore, accounting for future trends in mortality rates 
rather than assuming currently observed mortality rates 
may yield more valid estimations.
Hence, this study aims to provide estimates of YLL 
associated with diagnosed T2D and T2D-free life expec-
tancy for Germany that overcome these concerns. We use 
a mathematical model to estimate the burden associated 
with T2D in 2015 and project temporal trends up to 2040.
Methods
Study design
For this study, we considered the German population 
aged between 40 and 100  years in the years 2015 and 
2040. We defined the lower age limit of 40 years, because 
T2D prevalence at younger ages is relatively low [14]. The 
upper age limit was chosen based on the upper age limit 
in official population statistics [15].
In order to estimate T2D-free life expectancy and YLL 
at age 40 in 2015 and 2040 and to account for future 
trends in mortality and incidence rates, projections of 
these rates and the resulting prevalence of T2D were 
needed. The year 2100 was the upper bound of the pro-
jections in this setting, because a person aged 40 years in 
2040 would be 100 years in 2100. Hence, in order to esti-
mate T2D-free life expectancy and YLL associated with 
T2D for this person, the projected rates and prevalence 
between 2040 and 2100 were needed.
We used the mathematical model presented in the fol-
lowing section to project the age-specific incidence rate, 
mortality rates of people with and without T2D and 
the prevalence between 2015 and 2040. The projected 
parameters serve as input values to calculate T2D-free 
life expectancy and YLL associated with T2D. All analy-
ses were stratified by sex.
Mathematical model
The projection was based on the illness-death model. 
In this model, people can be in one of the three states 
“healthy”,”ill” and “dead”. In the current case, healthy and 
ill referred to the absence and presence of diagnosed 
T2D. Transitioning between states is expressed in terms 
of age and calendar time specific rates i (incidence rate 
from healthy to ill), m0 (mortality rate in the healthy 
state) and m1 (mortality rate in the ill state). The propor-
tion of the population in the ill state is the prevalence p . 
All parameters of the illness-death model depend on cal-
endar time t and age a . It has been shown that this system 
is governed by a partial differential equation [16, 17]:
(1)
(∂ t+∂a)p = (1− p) ·
[
i −m ·
p · (MRR − 1)
p · (MRR − 1)+ 1
]
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where (∂ t+∂a)p is the temporal change of the age-spe-
cific prevalence, m is the mortality rate of the general 
population, and MRR is the mortality rate ratio for peo-
ple with T2D versus without T2D ( m1/m0).
We solved Eq. (1) by integration using input values for 
the incidence rate, general mortality rate and MRR , to 
project the age-specific prevalence up to the year 2100.
Data sources
The projections were based on the age-specific preva-
lence and incidence rate of T2D observed in 2010 
among all people aged 40–100  years in the German 
statutory health insurance (N ≈ 65 million) [14]. People 
with prevalent T2D were identified by the correspond-
ing diagnostic codes of the International Classification 
of Diseases (E11) documented in inpatient or outpa-
tient care facilities. Prevalence of T2D among men and 
women aged ≥ 40  years was estimated with 7.4% and 
7.0%, respectively (see Additional file  1 for age-specific 
prevalence). The incidence rate was derived from a math-
ematical model that uses information on T2D prevalence, 
general mortality and MRR [14]. For men and women 
aged ≥ 40 years, the incidence rates were 16 and 13 cases 
per 1000 person years, respectively. Further details can be 
found in Tamayo et al. [14] and in Additional file 1. Infor-
mation on the age-specific diabetes-related MRR was 
based on the same data, but from the years 2013/2014 
[18]. Schmidt et  al. [18] estimated the MRR comparing 
6.5 million people with and 40.8 million people without 
diabetes (all types) in 2013 with regard to their vital sta-
tus in 2014. The MRR ranged between 6.9 among men 
aged 30–34  years and 1.1 among men aged ≥ 95  years 
(further details in Additional file  1). Although the MRR 
was not differentiated by diabetes type, these data serve 
as a reasonable approximation for the MRR associated 
with T2D, since 90% of cases are estimated to be of this 
type and the incidence rate of type 1 diabetes is highest 
in people younger than 20 years [19, 20]. The age-specific 
all-cause mortality rate in the general population ( m ) 
between 2010 and 2040 stems on the population projec-
tions of the Federal Statistical Office which is based on 
population statistics dating back to 1871 (Additional 
file  1) [15]. Based on this data from 2010, we projected 
the age-specific prevalence of T2D up to the year 2100 
and calculated T2D-free life expectancy and YLL in 2015 
and 2040. Further information on how Eq.  (1) can be 
used for projections is available in [21].
For each year beyond 2010, input values were chosen 
based on assumptions on temporal trends in the T2D 
incidence rate and the MRR . As base case, we chose a 
constant incidence rate, since long-term trends in the 
age-specific incidence rate are not available in Germany 
[22]. For the MRR , we assumed an annual decrease of 
2%, since there is consistent evidence from several coun-
tries that the MRR is decreasing with calendar time [4, 5, 
23]. However, since it seems unlikely that the difference 
in mortality between people with and without T2D will 
disappear completely, we assumed a lower limit of 1.1 for 
the MRR . In addition to the base case, we assumed three 
alternative scenarios (A, B and C) as depicted in Table 1. 
We chose these scenarios to account for uncertainty in 
the outcomes due to unknown future trends and to assess 
the impact of different trends in the incidence rate and 
the MRR on the outcomes. Since, the uncertainty in the 
results due to sampling error is very small compared to 
the variability between the different projection scenar-
ios, we focus on the variability due to unknown trends 
in incidence and mortality rates and do not report con-
fidence intervals. In Additional file  2, we show that the 
sampling error is negligible compared to the variability 
between the scenarios. Another reason to omit confi-
dence intervals is that the input data almost comprises 
the whole population (approximately 90%). Hence, infer-
ential statistics to generalize from a sample to the popu-
lation might not be necessary in this case.
Calculation of T2D‑free life expectancy
We used the method of Sullivan [24] to estimate T2D-
free life expectancy up to age 100:
where S is the survival function of the general popula-
tion based on projections of the mortality rate from the 
Federal Statistical Office (details in Additional file  3). 
For p , we used the projected prevalence from Eq.  (1). 
T2D-free life expectancy in a given year t was approxi-
mated by multiplying the probability of being free of 
T2D ( 1− p ) with the probability of being alive ( S ) for 
each year between age a = 40 and a = 100 . The integral 
of this product yields the T2D-free life expectancy at age 
40 years.
(2)







(1− p(t + u, a+ u))S(t + u, a+ u)du
Table 1 Scenarios of the prevalence projections
Assumed temporal trends in incidence and mortality between 2015 and 2040
Scenario Annual change in …
Incidence rate Mortality 
rate ratio
Base case 0 − 2%
A 0 0
B − 0.5% − 2%
C + 0.5% − 2%
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Calculation of years of life lost associated with type 2 
diabetes
Similar to previous studies [9, 25, 26], we estimated YLL 
as the difference in life expectancy between a person with 
T2D and a person of the same age without T2D. This 
approach is formally defined by the following equation:
where t and a are calendar time and age, respectively. 
SD− and SD+ are the survival functions of people without 
T2D and with T2D, respectively. These survival func-
tions were based on projections of the mortality rate m 
of the general population as reported by the Federal Sta-
tistical Office [15] and on the MRR reported by Schmidt 
et al. [18] to yield diabetes-specific mortality rates m1 and 
m0 (details in Additional file  3). For the calculation of 
YLL , we assumed that a person without T2D would not 
develop T2D after time t.
Henceforth, we refer to Eq. (3) as individual YLL , since 
it represents the comparison of two persons of the same 
birth cohort at a certain calendar time. As a population-






SD−(t + u, a+ u)− SD+(t + u, a+ u)du
YLL by summing up individual YLL over the age distribu-
tion in the population at time t . Population-wide YLL can 
be interpreted as the YLLs among those with prevalent 
T2D at time t . This population-wide YLL is not compa-
rable to the GBD approach, which sums up the remain-
ing life expectancies of people dying with T2D as the 
documented cause of death in death certificates. Since 
there are more people with prevalent T2D than people 
dying with T2D as the documented cause of death, it is 
expected that our approach results in more YLL com-
pared to the GBD approach.
Results
T2D‑free life expectancy
Figure  1 illustrates the survival probability for a person 
aged 40 years in 2015 up to age 100 in 2075, based on the 
projected mortality rate of the Federal Statistical Office. 
In addition, the figure illustrates the probability of being 
alive and free of T2D (“healthy”) for this person. Hence, 
for people in 2015 aged 40 years, one can infer the proba-
bility of being in the state “ill”, “healthy” or “dead” at each 
time point between 2015 and 2075. At age 100, the prob-
ability of being alive and healthy is very close to zero in 
all scenarios. Thus, we assume ages over 100 years to be 
negligible for this study.
Fig. 1 Survival and healthy survival probability of men and women aged 40 years in 2015. Different line patterns indicate different scenarios as 
depicted in Table 1. At each age, the healthy survival probability indicates the probability of being alive and free of type 2 diabetes. Base case: i  
constant, MRR − 2%; A: i  constant, MRR constant; B: i  − 0.5%, MRR − 2%; C: i  + 0.5%, MRR − 2%
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In Fig.  1, each of the three states of the illness-death 
model is designated by a corresponding area. Thus, the 
area below the healthy survival curve are the years spent 
in the “healthy” state, hence the T2D-free life expectancy, 
which were calculated using the formula by Sullivan [24]. 
It follows that the area between the overall survival curve 
and the healthy survival curve represents years spent in 
the “ill” state. The sum of T2D-free life expectancy and 
years spent in the “ill” state is the total life expectancy, 
which is equal to the area under the overall survival 
curve.
Table  2 shows the T2D-free life expectancy at age 
40  years for different scenarios in 2015 and 2040. The 
T2D-free life expectancy in 2015 for the base case were 
38.1  years and 32.7  years for women and men, respec-
tively. In 2040, T2D-free life expectancy is projected with 
39.1  years (absolute change: + 1.0  years) and 34.0  years 
(+ 1.3  years) among women and men, respectively. The 
base case assumed annual decreases of the MRR by 2%. 
Comparing the results to a scenario with constant MRR 
Table 2 Projected life expectancy free of type 2 diabetes (T2D-free LE) in 2015 and 2040
T2D-free LE refers to age 40
Scenarios assumed different annual trends in incidence rate ( i  ) and mortality rate ratio ( MRR ) associated with diabetes: Base case: i  constant, MRR − 2%; A: i  
constant, MRR constant; B: i  −  0.5%, MRR − 2%; C: i  + 0.5%, MRR − 2%




Base  case# 38.1 39.1 1.0 2.6
A 38.5 39.5 1.0 2.6
B 39.2 41.4 2.2 5.6
C 36.9 36.4 − 0.5 − 1.4
Men
Base  case# 32.7 34.0 1.3 4.0
A 33.2 34.5 1.3 3.9
B 33.7 36.4 2.7 8.0
C 31.6 31.5 − 0.1 − 0.3
Fig. 2 Survival probability at age 40 years in 2015 with and without 
type 2 diabetes (T2D). The survival functions for people with T2D in 
scenarios B and C in Table 1 were identical to the base case scenario. 
Base case: i  constant, MRR − 2%; A: i  constant, MRR constant; B: i  
− 0.5%, MRR − 2%; C: i  + 0.5%, MRR − 2%
Table 3 Years of life lost (YLL) associated with type 2 diabetes on 
the individual level
YLL refer to age 40 years on in the year 2015 and 2040.
Scenarios assumed different annual trends in incidence rate ( i  ) and mortality 
rate ratio ( MRR ) associated with diabetes: Base case: i  constant, MRR − 2%; A: i  
constant, MRR constant; B: i  − 0.5%, MRR − 2%; C: i  + 0.5%, MRR − 2%
Scenario YLL in 2015 
(in years)









Base case 1.6 0.7 − 0.9 − 56.3
A 4.2 3.1 − 1.1 − 26.2
B 1.6 0.7 − 0.9 − 56.3
C 1.6 0.7 − 0.9 − 56.3
Men
Base case 2.7 1.1 − 1.6 − 59.3
A 5.8 4.5 − 1.2 − 22.4
B 2.7 1.1 − 1.6 − 59.3
C 2.7 1.1 − 1.6 − 59.3
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(scenario A), shows that trends in MRR only had minor 
influence on T2D-free life expectancy. In contrast, minor 
annual changes in the incidence rate of ± 0.5% (scenarios 
B and C) had a comparably large impact on T2D-free 
life expectancy in 2040. Decreases in the incidence rate 
resulted in an increase of T2D-free life expectancy by 
2.2 years and 2.7 years among women and men, respec-
tively. In contrast, increases in the incidence rate resulted 
in a decrease in T2D-free life expectancy by 0.5 years and 
0.1 years among women and men, respectively.
Years of life lost associated with type 2 diabetes
Figure  2 illustrates the survival curves for people with 
and without T2D with regard to different assumptions 
on the incidence rate and MRR . In the base case as well 
as scenarios B and C we assumed a decreasing MRR . 
In these scenarios people with T2D had a considerably 
higher survival probability compared to assuming con-
stant MRR (scenario A). Contrary, temporal trends of the 
incidence rate (scenario B and C) had almost no impact 
on survival of the diabetic population.
The areas between the curves for no T2D and the 
curves for the T2D scenarios represents the YLL for a 
person aged 40  years in 2015 with T2D compared to a 
person aged 40  years in 2015 without T2D. Hence, one 
can see from Fig. 2 that changes in MRR have a consider-
able impact on YLL.
We calculated this area for each scenario in 2015 and 
2040 using Eq.  (3) (Table 3). In the base case, men and 
women with T2D aged 40  years in 2015 lost 2.7 and 
1.6 years, respectively, compared to a same aged person 
without T2D. In 2040, the results indicate a substan-
tial decrease in YLL by 0.9  years and 1.6  years among 
women and men, respectively. Assuming constant 
instead of decreasing MRR (scenario A) resulted in more 
than twice as many YLLs compared to the base case 
scenario in 2015. Also the decrease of YLL in 2040 was 
much weaker.
We summed up age-specific individual YLL for people 
aged 40 to 100  years to calculate population-wide YLL 
(Table  4). Overall, YLL decreased from 10.8 million in 
2015 to 6.4 million (− 4.4 million years) in 2040 in the 
base case scenario. In contrast to the base case scenario, 
assuming constant MRR increased population-wide YLL 
by 4.1 million years. Unlike individual YLL , population-
wide YLL in 2040 are strongly affected by trends in the 
incidence rate (scenario B and C).
Discussion
Main findings
Assuming a constant incidence rate, we found that 
women and men at age 40 years in 2015 will live approxi-
mately 38  years and 33  years free of diagnosed T2D, 
respectively. Up to the year 2040, these numbers are pro-
jected to increase by 1.0 years and 1.3 years. However, we 
also found that small annual changes in future incidence 
rates strongly influence these trends. For instance, an 
annual increase in the incidence rate of 0.5% would result 
in decreases of T2D-free life expectancy by − 0.5  years 
and − 0.1  years among women and men, respectively, 
Table 4 Years of life lost (YLL) associated with type 2 diabetes on the population level
Scenarios assumed different annual trends in incidence rate ( i  ) and mortality rate ratio ( MRR ) associated with diabetes: Base case: i  constant, MRR − 2%; A: i  
constant, MRR constant; B: i  − 0.5%, MRR − 2%; C: i  + 0.5%, MRR − 2%






Base case 4.87 2.77 − 2.10 − 43.2
A 8.33 10.11 1.78 21.3
B 4.85 2.56 − 2.29 − 47.2
C 4.89 2.99 − 1.90 − 38.3
Men
Base case 5.88 3.58 − 2.30 − 39.1
A 10.28 12.63 2.35 22.9
B 5.86 3.31 − 2.54 − 43.4
C 5.91 3.87 − 2.04 − 34.5
Overall
Base case 10.75 6.35 − 4.40 − 41.0
A 18.61 22.74 4.13 22.2
B 10.70 5.87 − 4.83 − 45.1
C 10.80 6.86 − 3.94 − 36.5
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whilst an analogous decrease results in 2.2  years and 
2.7 years increase in T2D-free life expectancy. Trends in 
MRR had no relevant impact on T2D-free life expectancy.
Assuming a continued decrease in MRR of 2% per year, 
we found that women and men aged 40 years with diag-
nosed T2D in 2015 lose 1.6 and 2.7 years of life, respec-
tively, compared to a same aged person without T2D. 
In 2040, these numbers would reduce by approximately 
0.9  years and 1.6  years. These reductions will be much 
smaller, if excess mortality does not improve after 2015. 
Trends in T2D incidence had no relevant impact on 
individual YLL associated with T2D. In the whole Ger-
man population aged ≥ 40  years, YLL associated with 
T2D amounted to 10.8 million years in 2015 in case of 
an annual decrease in MRR of 2%. In 2040, this number 
will decrease by 4.4 million years. Depending on annual 
increases or decreases in the incidence rate of 0.5%, pop-
ulation-wide YLL will decrease by 3.9 million years or 4.8 
million years, respectively. In case of no further improve-
ments in MRR , population-wide YLL would strongly 
increase to 18.6 million years in 2015 and further increase 
by 4.1 million years until 2040. In this scenario, YLL were 
already higher in 2015, because people with T2D would 
experience the higher MRR beyond 2015, in contrast to 
decreasing MRR in the other scenarios.
Comparison to previous studies
In general, some previous studies estimated lower T2D-
free life expectancy than we did. For instance, a regional 
German study estimated T2D-free life expectancy at age 
40 years in 2014 with 34 years and 29 years for women and 
men, respectively [12], compared to 38 years and 33 years 
in our study. Cunningham et  al. [13] reported T2D-free 
life expectancy of 30 years and 33 years at age 40 years in 
2004 for men and women in the U.S. In Australia, men and 
women aged 45  years between 2000 and 2005 were esti-
mated to live 30 and 34 years without T2D [27]. However, 
direct comparisons of these results are problematic, since 
most studies relied on cross-sectional mortality rates and 
(implicitly) assumed that these remain constant beyond 
the study period. In contrast, we used projected prevalence 
and simultaneously accounted for projected decreases in 
general mortality and MRR . Besides different study popu-
lations and time periods, these different methodological 
approaches might explain why we estimated higher T2D-
free life expectancy. Accordingly, Cunningham et  al. [13] 
found that fixing general mortality rates at levels observed 
between 1980 and 1989, results in much lower T2D-free 
life expectancy between 2000 and 2005, compared to using 
observed mortality rates between 2000 and 2005. They 
concluded that potential reductions in T2D-free life expec-
tancy due to increases in incidence rates were partly offset 
by decreases in general mortality rates. This is in line with 
our finding that T2D-free life expectancy will increase up to 
the year 2040, even if the incidence rate remains constant.
A similar reasoning holds for the comparison of previ-
ous studies estimating YLL associated with T2D. In gen-
eral, we found lower YLL on the individual level compared 
to studies from other countries [9, 25–29]. Assuming 
continuing decreases in T2D-associated excess mortal-
ity, we estimated that women and men aged 40  years in 
2015 will lose 1.6 years and 2.7 years, respectively. Other 
studies estimated YLL s between 3.5 years among Swedish 
men aged 40 years in 2013 [29] and 8.5 years among Dan-
ish men aged 40 between 1995 and 2008 [9]. This range 
covers our results in the scenario assuming constant MRR 
(scenario A). Hence, the lower YLL in our base case sce-
nario are probably mainly caused by assuming continuing 
decreases in general as well as excess mortality.
Due to different population sizes, our population-wide 
estimates of YLL cannot be compared to other countries. 
The GBD provides country-specific YLL s on the popula-
tion level. However, the method is based on T2D-related 
deaths documented in death certificates and does not 
consider prevalent cases. Using this method, it was esti-
mated that 256,217  years were lost among deaths with 
T2D as the documented cause of death in 2015 [10]. 
As expected, this is far below our estimate of 10.8 mil-
lion YLL associated with T2D, since our approach sum-
marizes all individual differences in life expectancies 
between people with prevalent T2D compared to same-
aged persons without T2D.
Implications for public health
Given assumed trends in general mortality and excess 
mortality associated with T2D, the results suggest a 
substantial improvement of YLL associated with T2D 
and T2D-free life expectancy in the German popula-
tion between 2015 and 2040. This should motivate fur-
ther efforts to lower the incidence and excess mortality 
of T2D. This is particularly important, because we also 
found that increases in incidence and a sustained high 
T2D-associated excess mortality would lead to substan-
tial increases in disease burden.
The results may be used to inform about the impact 
of future efforts in treating and preventing T2D. In this 
regard, two different mechanisms could be the target 
of interventions. Measures generally known as ‘pri-
mary prevention’ aim to prevent disease and thus tar-
get the incidence rate [30]. Given an effective measure 
of primary prevention, this would impact T2D-free life 
expectancy and YLL on the population level, but would 
not improve YLL in individuals with T2D. Examples for 
primary prevention include taxes on unhealthy products 
(e.g. sugar-sweetened beverages), food labeling and set-
ting based approaches that support healthy food choices 
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[31, 32]. With regard to food labeling, the nutriscore was 
recently introduced to Germany [33].
Contrary, tertiary prevention strategies aim at reduc-
ing the risk of complications among those with the dis-
ease [30], for instance by optimizing glucose control or 
screening for early stages of complications. One example 
for tertiary prevention in Germany are disease manage-
ment programs for diabetes, which are structured mod-
els of diabetes care provided by health care institutions 
in cooperation with health insurances. This type of pre-
vention may improve excess mortality of T2D and thus 
mainly improve YLL on the individual and population 
level, but not the T2D-free life expectancy.
In light of past decreases in excess mortality observed 
in other countries, health care systems were rather suc-
cessful with regard to tertiary prevention [6, 7]. In con-
trast, heterogeneous trends in the incidence rate across 
countries do not suggest consistent improvements with 
regard to primary prevention [23, 34–37]. One might 
conclude that enhanced efforts of primary prevention are 
warranted, both to increase T2D-free life expectancy and 
decrease population-wide YLL associated with T2D.
Another important implication is that the meth-
ods used to estimate YLL and T2D-free life expectancy 
strongly influence the results. Here, we argue that these 
measures of disease burden involve assumption on future 
trends by definition, since they rely on life expectancy. 
Hence, incorporating best available evidence on future 
trends of mortality and incidence rates may yield more 
valuable estimates to inform policy than assuming cur-
rently observed rates [8].
Strengths and limitations
This is the first study that projects the future burden of 
T2D in terms of YLL associated with T2D and T2D-free 
life expectancy based on data comprising approximately 
90% of the population in Germany. Previous studies in 
the German context reported only one of these measures 
and did not project future trends in the disease burden 
associated with T2D. The estimation of YLL and T2D-
free life expectancy in this study was based on projected 
incidence and mortality rates. Compared to assum-
ing currently observed rates, this may be a more valid 
approximation because these measures are a function 
of life expectancy which inherently involve future mor-
tality rates. This is particularly relevant when assessing 
time trends in YLL and T2D-free life expectancy. For 
instance, Muschik et  al. [12] found a decrease in T2D-
free life expectancy between 2005 and 2014, using period 
life tables. It is not clear if these decreases are due to 
increases in incidence or due to ignoring future trends 
in mortality. Our results suggest, that T2D-free life 
expectancy increases even if the incidence rate remains 
constant, because of decreasing overall mortality. Hence, 
in the case of Muschik et  al., one might conclude that 
the population will have shorter life time without T2D, 
without knowing if this would also be concluded if future 
trends in mortality were incorporated.
As a drawback, we had to rely on more or less specula-
tive assumptions on future trends. This may be particu-
larly problematic given the long projection over 85 years 
up to the year 2100. While future mortality rates of the 
general population are based on sound data dating back 
to 1871, assumptions on trends in the incidence rate were 
rather arbitrary. In fact, the input data for the incidence 
originates from 2010, which is quite dated. Given hetero-
geneous trends in Europe [23, 34–37], we were not able 
to establish a most plausible trend in incidence. Hence, 
we assumed constant incidence rates from 2010 onwards 
in the base case scenario and additionally included sce-
narios with varying time trends to address the lack of 
input data. With regard to trends in MRR , we mostly 
relied on data outside of Germany. In contrast to trends 
in the incidence rate, there is consistent evidence from 
several high income countries that the MRR decreased 
over the last decades. Hence, we assumed a continued 
decrease in the base case scenario and compared the 
results to a scenario with constant MRR . Some stud-
ies suggest that the trends in MRR differ between age 
groups [38]. For instance, in Australia, it was estimated 
that decreases in the MRR only occurred among people 
aged ≥ 80 years [39]. However, due to the lack of data in 
Germany, we assumed the same trend in MRR for all age 
groups. Technically, age-specific trends in MRR could be 
incorporated into the projection model.
Another debatable issue in our analysis is that in order 
to calculate YLL , we assumed that a person without T2D 
at a given age and in a given year will not develop T2D 
after that year. Of course, this is an unrealistic assump-
tion. Nevertheless, it provides valuable information, since 
YLL can then be interpreted as the potential life years 
that would be gained, if excess mortality associated with 
T2D was non-existent. The model we used would allow 
to incorporate the more realistic setting, in which per-
sons could develop T2D after a given year. However, the 
resulting YLL estimate would be lower in scenarios with 
increasing incidence rates, because persons without T2D 
in a given year would be more likely to develop T2D and 
subsequently experience higher mortality rates. Meas-
ures of disease burden that indicate lower disease bur-
den when the incidence rate increases are not useful to 
inform public health.
Finally, our study only considers diagnosed T2D, since 
we used data from statutory health insurance. Hence, our 
results do not consider people with undiagnosed T2D 
and those who did not seek health care in a given year. 
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Furthermore, people in private health insurance are not 
included, which can be considered a minor issue, given 
that approximately 90% of the population in Germany is 
in statutory health insurance.
Conclusions
Given an assumed decrease in mortality and no increases 
in T2D incidence, the mortality burden in people with T2D 
will strongly decrease on the individual as well as on the 
population level. In addition, the lifetime without T2D is 
likely to increase. However, due to improved survival, peo-
ple will also have longer lives with T2D which will further 
shift the disease burden from mortality to morbidity. The 
projected improvements in disease burden strongly depend 
on future improvements of excess mortality associated with 
T2D and the incidence of T2D, which should motivate 
increased efforts of primary and tertiary prevention.
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